AU2021248212A1 - Methods of administering an aripiprazole injectable preparation - Google Patents

Methods of administering an aripiprazole injectable preparation Download PDF

Info

Publication number
AU2021248212A1
AU2021248212A1 AU2021248212A AU2021248212A AU2021248212A1 AU 2021248212 A1 AU2021248212 A1 AU 2021248212A1 AU 2021248212 A AU2021248212 A AU 2021248212A AU 2021248212 A AU2021248212 A AU 2021248212A AU 2021248212 A1 AU2021248212 A1 AU 2021248212A1
Authority
AU
Australia
Prior art keywords
aripiprazole
injectable preparation
salt
patient
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021248212A
Other languages
English (en)
Inventor
Matthew HARLIN
Arash Raoufinia
Xiaofeng Wang
Yanlin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021248212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2021248212A1 publication Critical patent/AU2021248212A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
AU2021248212A 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation Pending AU2021248212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Publications (1)

Publication Number Publication Date
AU2021248212A1 true AU2021248212A1 (en) 2022-12-01

Family

ID=75581573

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021248212A Pending AU2021248212A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation
AU2021245713A Pending AU2021245713A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021245713A Pending AU2021245713A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Country Status (16)

Country Link
US (6) US20230129919A1 (https=)
EP (3) EP4467194A3 (https=)
JP (4) JP7733000B2 (https=)
KR (3) KR20220161402A (https=)
CN (3) CN115379842A (https=)
AU (2) AU2021248212A1 (https=)
BR (2) BR112022018721A2 (https=)
CA (3) CA3163321C (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012354A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TW202523329A (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére
CA3197997A1 (en) 2023-03-17 2025-01-23 Otsuka Pharmaceutical Co., Ltd. METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4082546A1 (en) 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére

Also Published As

Publication number Publication date
JP2025020306A (ja) 2025-02-12
EP3941470A1 (en) 2022-01-26
KR20240165486A (ko) 2024-11-22
TW202523329A (zh) 2025-06-16
JP7733000B2 (ja) 2025-09-02
EP4467194A3 (en) 2025-01-08
JP7584535B2 (ja) 2024-11-15
US20220160621A1 (en) 2022-05-26
MX2022012353A (es) 2022-10-31
KR102732030B1 (ko) 2024-11-20
CA3212191A1 (en) 2021-10-07
CA3163321C (en) 2023-12-19
CN115379842A (zh) 2022-11-22
EP4467194A2 (en) 2024-11-27
CA3163321A1 (en) 2021-10-07
WO2021201239A1 (en) 2021-10-07
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
US20240374506A1 (en) 2024-11-14
EP4125903B1 (en) 2024-10-09
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
CN115397420A (zh) 2022-11-25
US20230129919A1 (en) 2023-04-27
TWI865760B (zh) 2024-12-11
KR20220161402A (ko) 2022-12-06
US20260115131A1 (en) 2026-04-30
JP2023520004A (ja) 2023-05-15
EP4125903C0 (en) 2024-10-09
JP2023519425A (ja) 2023-05-10
TW202200141A (zh) 2022-01-01
JP2025176037A (ja) 2025-12-03
US20260034053A1 (en) 2026-02-05
TWI906279B (zh) 2025-12-01
EP4125903A1 (en) 2023-02-08
PL4125903T3 (pl) 2025-02-03
BR112022018721A2 (pt) 2022-11-01
AU2021245713A1 (en) 2022-12-01
HUE069157T2 (hu) 2025-02-28
US20230225962A1 (en) 2023-07-20
WO2021201238A1 (en) 2021-10-07
ES2995466T3 (en) 2025-02-10
CA3136727A1 (en) 2021-10-07
MX2022012354A (es) 2022-10-31
CN119792290A (zh) 2025-04-11
BR112022018647A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
US20260115131A1 (en) Methods of administering an aripiprazole injectable preparation
JP5683810B2 (ja) メトトレキセート濃厚溶液
EP3785698A1 (en) Edaravone pharmaceutical composition
US12329740B2 (en) Rescue treatment of post operative nausea and vomiting
AU2015323321A1 (en) Long acting pharmaceutical compositions
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
AU2011273064A1 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
HK40120297A (en) Methods for dose initiation of aripiprazole treatments
US20170165210A1 (en) Pharmaceutical Compositions Comprising Paracetamol and Process for Preparing The Same
EP4527373A1 (en) New formulations of amisulpride
HK40081123B (en) Methods for dose initiation of aripiprazole treatments
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
HK40063844B (zh) 一种药物组合物及其应用